Invitation to the Annual General Meeting

Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Tuesday, September 28th, 2021 at 11:00…

Read more

Prior myocardial infarction, coronary artery disease extent, diabetes mellitus, and CERT2 score for risk stratification in stable coronary artery disease

Hilvo et al. European Journal of Preventive Cardiology. Published 28 August 2021

Read more  

Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients

Leiherer et al. European Journal of Preventive Cardiology. Published: 21 August 2021

Read more  

Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus

Hilvo et al. European Heart Journal Open, Published: 13 July 2021

Read more  

Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts

Hilvo et al. European Journal of Preventive Cardiology, Published 01 June 2021

Read more  

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

Salminen et al. Cancers 2021, 13(8), 1764.

Read more  

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test

Zora Biosciences Oy announced it has signed a license agreement with Quest Diagnostics, the world leader in diagnostic information services, for Zora’s patented ceramide-analysis technology.

Read more

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome

Gencer et al. 2020 European Journal of Preventive Cardiology. Published online Dec 2020

Read more  

Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors

Meeusen et al. 2020 Clinica Chimica Acta 511 (2020) 138–142

Read more  

Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification

Hilvo et al. 2020. Frontiers in Endocrinology. September 2020 | Volume 11 | Article 570628

Read more  

Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography

Mantovani et al. 2020 Diabetes & Metabolism, 46(2):150-157.

Read more  

Zora is part of major European heart disease prevention project

The project is executed together with European Society of Cardiology, ESC, and National Institute for Health and Care Excellence, NICE, as well as cardiologists throughout the Europe.

Read more

Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

Hilvo et al. 2020 JAHA, Published Online May 2020

Read more  

LDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients

New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests

Read more

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients

Hilvo et al. 2019 Eur Heart J. Published online: 18 June 2019

Read more  

Zora Biosciences Pushing Ceramide Testing to Assess Cardiovascular Risk

Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.

Read more

Zora Brings Molecular Lipids to the Clinic for Cardiovascular Risk Prediction with Enhanced Capacity

Zora’s laboratory has been able to improve its robotized mass spectrometry workflow such that one machine is able to analyze up to 12 000 samples per…

Read more

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths

Ruuth M. et al. 2018 European Heart Journal, 2018: 39 (27),2562–2573.

Read more  

Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients

Anroedh et al. 2018 The Journal of Lipid Research. June 1, 2018, doi: 10.1194/jlr.P081281

Read more  

Zora participates XXXVI Nordic Congress in Clinical Chemistry -congress in June at Helsinki

Zora participates XXXVI Nordic Congress in Clinical Chemistry in June 12-15, 2018 at Helsinki, Finlandia Hall. Nordic Congress in Clinical Chemistry is notable event in…

Read more